Nebenwirkungen · Ontozry
Ontozry 12.5 mg tablets Ontozry 25 mg film-coated tablets Ontozry 50 mg film-coated tablets Ontozry 100 mg film-coated tablets Ontozry 150 mg film-coated tablets Ontozry 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11–12
HOS-146973 · Präparat HOS-099586
At the time of prescription, patients should be advised of the signs and symptoms of DRESS and monitored closely for skin reactions. Symptoms of DRESS include typically, although not exclusively, fever, rash associated with other organ system involvement, lymphadenopathy, liver function tests abnormalities and eosinophilia. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If signs and symptoms suggestive of these reactions appear, cenobamate should be withdrawn immediately and an 11 alternative treatment considered (as appropriate). Ontozry should always be initiated at 12.5 mg once daily and titrated not faster than once every two weeks (see sections 4.2 and 4.4.).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T14:34:00Z · SHA-256 d92fc56a78db2eea603a783fcef851978cab1d09f2b484d153e68bbcbe1ca04d · Passage de3e38af9290e4a9ed096582b8e8ecd933c3883e96104d49df8b446ad2e5d361 · Zeichen 3578–4407 im Abschnitt